Abstract
Cancer remains one of the most fatal disease threats to mankind. As the development of healthcare and medical science it is important to come up with a sustainable solution to deal with cancer treatment. Despite the fact that many of the approved drugs still exhibit high systemic toxicity, primarily as a result of their lack of tumor selectivity and current pharmacokinetic drawbacks (such as low water solubility), which adversely affect drug circulation time and bioavailability, anticancer research has produced impressive results in recent decades. The sensitivity of anticancer medications to various parameters has been proven by stability tests, which were conducted under gentle settings during their formation or during stressful exposure to high temperature, hydrolytic media, or light source. Because of this, the development of degradation products is evaluated in pharmaceutical formulations as well as in hospital waste released into the environment. Many formulations have been created to date with the goals of enhancing medication stability, lowering hazardous side effects, and attaining tissue-specific drug targeting. In targeted cancer therapy, the creation of prodrugs offers a viable approach to enhancing the stability, effectiveness, and selectivity of active ingredients. According to recent research, anticancer medications can be made more soluble, stable, and pharmacokinetic by incorporating them into vesicular systems like polymeric micelles or cyclodextrins or by using nanocarriers containing chemotherapeutics that bind to monoclonal antibodies. In this work, we provide an overview of the most recent developments in our understanding of the creation of potent, very stable anticancer medications that are either encapsulated in nanosystems or designed as stable prodrugs.